Doshi, Jalpa ALi, PengxiangHuo, HairongPettit, Amy RKumar, RishabWeiss, Brendan MHuntington, Scott F2023-05-222023-05-222016-04-012016-09-01https://repository.upenn.edu/handle/20.500.14332/38231Medicare Part D beneficiaries with higher out-of-pocket costs are more likely to delay starting or not start a recommended specialty drug when newly diagnosed with leukemia. Policy changes are needed to ensure optimal access to specialty medications under Medicare Part D.http://creativecommons.org/licenses/by-nd/4.0/health insurancemedicareHealth Services AdministrationHealth Services ResearchHigh Cost Sharing and Specialty Drug Initiation Under Medicare Part D: A Case Study in Patients With Newly Diagnosed Chronic Myeloid LeukemiaBrief